Abstract
# Hot Take: The FDA Just Quietly Moved 12 Peptides — And It's Not What Most Clinics Are Telling You ## What happened Effective **April 22, 2026**, the FDA removed **12 peptides** from the 503A Category 2 bulks list — the list of substances with significant safety or efficacy questions that compounding pharmacies can't use. The action was a procedural removal, not an affirmative clearance. The 12 peptides: **Going to PCAC review on July 23, 2026:** BPC-157, KPV, MOTs-C, TB-500 **Going to PCAC review on July 24, 2026:** DSIP (Emideltide), Epitalon, Semax **Going to PCAC review by February 2027:** LL-37 (Cathelicidin), DiHexa, GHK-Cu (all routes of administration), PEG-MGF, Melanotan II Within 24 hours of the announcement, half the peptide influencer world declared "peptides are legal again." That framing is wrong, and running with it is how clinics end up on an FDA warning letter. Here's what actually happened — and why it still matters. --- ## What this decision is — and isn't **What it is:** A procedural removal. The nominators who originally asked the FDA to evaluate these peptides for Category 1 (cleared for compounding) withdrew their nominations. The FDA then removed the peptides from Category 2 seven calendar days after publication because there was no active petition to review. **What it isn't:** An affirmative ruling that these compounds are safe, effective, or cleared for compounding. The FDA did not vote "yes" on any of them. They were removed because no one is asking the question anymore — not because the FDA answered it. **What that means in practice:** Between April 22 and the upcoming PCAC meetings, compounding pharmacies sit in a regulatory gray zone. Technically not on the restricted list. Still not formally cleared. The FDA can issue guidance, warning letters, or enforcement actions at any point in that window. Treating it as a green light is a misread of how the FDA actually moves. **Note on GLP-1s:** This action does NOT include semaglu…
All information is presented for Research Use Only (RUO). Not medical advice.